United Therapeutics Corporation Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
United Therapeutics Corporation (UTHR) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $73.89 million for the 3-month period ending 2011-06-30, per its 10-Q filed 2011-07-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2011-07-28
- United Therapeutics Corporation income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2011-06-30 was $73.89M, a 94.62% increase year-over-year.
- United Therapeutics Corporation income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2010-06-30 was $37.97M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month |
|---|---|---|
| 2011-06-30 | $73.89M 10-Q · filed 2011-07-28 | $93.25M 10-Q · filed 2011-07-28 |
| 2010-06-30 | $37.97M 10-Q · filed 2011-07-28 | $56.91M 10-Q · filed 2011-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |